Table 1 Patient and disease characteristics
FEATURES: | Number of patients (total 8): |
|---|---|
GENDER: | |
Male | 5 |
Female | 3 |
AGE (years): | |
Mean | 68.4 |
Range | 57–80 |
ECOG PERFORMANCE STATUS: | |
0–1 | 6 |
2–3 | 2 |
PRIMARY TUMOR SITE: | |
Skin | 1 |
Breast | 1 |
Lung | 6 |
HISTOLOGY: | |
Adenocarcinoma (lung) | 3 |
Adenocarcinoma (breast) | 1 |
Squamous (lung) | 3 |
Malignant melanoma | 1 |
TREATED BULKY TUMOR SITE: | |
Lung primary | 6 |
Neck lymph node metastasis (skin melanoma) | 1 |
Bone metastasis (breast) | 1 |
BULKY TUMOR PATIENTS WITH DISTANT OLIGOMETASTASES: | 3 |
Lung primary(1), malignant melanoma (1), Breast(1), | |
BULKY TUMOR PATIENTS WITH LYMPH NODE METASTASES ONLY: | 5 |
Lung primary(5) | |
UNRESCTABLE BULKY TUMOR DIAMETER: mean/range (cm) | 10.1/6.6–13.8 |
UNRESCTABLE BULKY TUMOR VOLUME: mean/range (cm3) | 375.4/121.5–901.8 |
TARGETED BULKY TUMOR HYPOXIC SEGMENT: mean/range (cm3) | 124.7/41.9–442.9 |
SYSTEMIC THERAPY (exclusively before SBRT-PATHY) | |
Chemotherapy | 1 |
Immunotherapy | 1 |
SYMPTOMS related to bulky disease: | |
Pain | 6 |
Dyspnea | 7 |
Cough | 5 |
Haemoptysis | 2 |
PATIENTS TREATED AT “MOST FAVOURABLE” DAY: | 4 |
Lung primary: squamous(1) and adenocarcinoma(1) | 2 |
Neck lymph node metastasis of malignant melanoma of the skin | 1 |
Bone metastasis of breast adenocarcinoma | 1 |
PATIENTS TREATED AT “LEAST FAVOURABLE” DAY: | 4 |
Lung primary: squamous(2) and adenocarcinoma(2) | 4 |